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Reply to “The effect of smoking on exacerbation risk in eosinophilic patients with 
chronic obstructive pulmonary disease” 
We thank the authors for raising these comments and would like to explain the rationale 
behind our chosen strategy of analyses. 
Our previous work on risk factors of frequent COPD exacerbations confirms the authors’ 
statement that a recent history of exacerbations is the strongest risk predictor of future 
exacerbations.1 This strong association is probably caused by factors, mostly unknown, that 
are consistently present and influencing the degree of airway inflammation.2 One of these 
factors may be increased migration of eosinophils from the circulation to the airways.3 Little is 
known about the long-term course of eosinophilic airway inflammation in COPD, but some 
patients may have persistent eosinophilic inflammation, whereas in others eosinophilic 
inflammation may be intermittently present. This theory is supported by our unpublished work 
analysing the stability of blood eosinophil counts over time in patients diagnosed with COPD 
from the Optimum Patient Care Research Database (OPCRD; 
http://optimumpatientcare.org/), in which we find a within-patient correlation coefficient of 
0.56. 
We agree with the authors that it is important to correct for baseline differences in 
exacerbation rates between study arms when studying effectiveness of specific interventions 
to achieve comparison groups that are similar in exacerbation risk at the start. By doing so, a 
potential change in exacerbation rate from baseline to outcome year caused by the 
intervention will be the focus of the outcome analyses. 
However, the aim of our observational study, like similar studies4, was to evaluate the 
association between blood eosinophil counts and exacerbation risk of patients with COPD. 
Patients with persistent eosinophilic inflammation are likely to have increased rates of 
exacerbations over both the baseline and the outcome year due to the same underlying 
mechanism. These persistent effects would be dampened by additional adjustment for the 
baseline exacerbation rate, which would change the focus towards a change in exacerbation 
rate from baseline to outcome period. In our opinion, the baseline exacerbation rate does not 
fulfil the definition of a real confounder, i.e. an extraneous factor that is associated with the 
exposure under study (eosinophils) and also predictive of disease occurrence 
(exacerbations)5 but instead is an intermediate factor on the pathway from persistent 
recruitment of eosinophils to exacerbations. The suggested adjustment could thus be defined 
as an overadjustment in the context of intermediate variables, which would bias the results 
towards the null.6 
Indeed, the rate ratio of the association in ex-smokers is reduced from 1.32 to 1.18 (95% 
confidence interval; 1.04-1.34) when the analyses were additionally adjusted for the number 
of baseline exacerbations, which nonetheless is still significant, suggesting that some of the 
effect is caused by varying eosinophil levels. 
The authors also suggest that a so-called “healthy smoker effect” may have biased the 
association between blood eosinophil count and exacerbation rate, namely, the tendency of 
people who tolerate cigarettes to continue smoking, whereas those who experience serious 
health problems tend to quit.7 We cannot fully rule this out, but there is no reason to assume 
that this tendency would be very different between patients with and without high blood 
eosinophil counts, unless the health problems are related to these counts. Moreover, 43% of 
all patients were still smoking, as were 39% of patients with frequent exacerbations in the 
baseline year, illustrating that smoking cessation can be very difficult for patients with COPD. 
We acknowledge the authors’ concern regarding the potential for selection bias; however, a 
full blood count is a common blood test to check a person’s general health or to screen for 
conditions such as anaemia, which will limit the amount of eosinophil group misclassification 
due to the presence of unknown acute co-existing inflammatory illness. Additional adjustment 
for comorbidities did not relevantly influence the results. 
Finally, we would like to emphasise that further research is needed to shed more light on our 
observations. 
Marjan Kerkhof, Elizabeth V.Hilllyer and David B. Price on behalf of all authors. 
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